



Contact:
Cardisio USA
info@cardis.io

Cardisio GmbH Acquires Assets of Enverdis GmbH

Addition of Diagnostic Products, Research Data, Patents and Technology Complements Cardisio's Platform for AI-Based Heart Health

Frankfurt, Germany, January 31., 2022—Cardisio GmbH, developer of the world's first non-invasive, highly accurate screening method for heart diseases, today announced the acquisition of the assets of Enverdis GmbH, an innovator in cardiovascular functional diagnosis. With this acquisition, Cardisio deepens its technology, research data and product portfolio in the market for AI-based heart health.

Enverdis, based in Dusseldorf, Germany, is the developer of the Cardiologic Explorer, which offers broad, non-invasive and fast diagnoses of various heart diseases. Its second flagship product, Vascular Explorer, a device for automated arterial analysis, has been used as gold standard for the 'National Cohort' study, a common resource for studies on the risk factors and etiologic mechanisms of major diseases in the German population.

Existing Enverdis customers will be offered upgrades to Cardisio's innovative Cardisigraphy technology, the industry's most advanced non-invasive method for early detection of heart diseases.

"We are very pleased about the merger, as we now combine 26 years of practical experience in research and application of vector cardiography," said Meik Baumeister, co-founder and CEO of Cardisio. "The combined research data results, as well as the market presence of Enverdis' products, offer us significant potential in the further development and marketing of methods for the early detection and diagnosis of cardiovascular diseases."

"We are very happy about our companies joining forces. Together we can achieve significantly more and the competencies of our two companies complement each other perfectly," said Walid Fakhry, Chairman of Enverdis. "I look forward to continuing my personal active support of Cardisio in the future."

About Cardisigraphy

People with heart diseases are usually symptom-free until the onset of a heart attack. The Cardisigraphy test is so reliable and easy to use, it can detect heart disease early, allowing for preventive treatment to avoid a potentially fatal heart attack.

Cardisigraphy analyzes the individual three-dimensional electrophysical profile of the heart and recognizes pathological patterns of heart diseases using a proprietary algorithm and neural networks (AI). The test requires a PC to access the web service (Cardisio Cloud), a data collector (e.g. a Cardisigraph) and commercially available ECG cables as well as five disposable electrodes.

Cardisigraphies are currently available for investigational use only in the United States. Final performance specifications and claims are subject to change pending the completion of regulatory market-access activities.

About Cardisio GmbH

Cardisio GmbH is a mobile health tech company that uses artificial intelligence in the world's first and only non-invasive screening test for coronary and structural heart diseases. The Cardisigraphy



test is easy to administer, low cost and unprecedented in its accuracy. Cardisio GmbH is headquartered in Frankfurt, Germany, and has offices in Berlin and San Francisco. For further information, visit www.cardis.io or e-mail info@cardis.io.

Cardisio™ is a registered trademark of Cardisio GmbH.